Who Makes Kisqali and Why is Safety a Concern?
Kisqali, also known as ribociclib, is a medication developed by Novartis [1], a leading pharmaceutical company. Kisqali is used to treat hormonally receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. Given its relatively recent approval in 2017, safety concerns and patent expirations are worth examining.
Clinical Data for Kisqali's Safety
The most significant clinical trials for Kisqali include the MONALEESA trials series, which demonstrated Kisqali's efficacy and safety in treating advanced breast cancer. Results showed that Kisqali improved progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer when combined with an aromatase inhibitor [2]. A subsequent trial found similar results when paired with fulvestrant [3]. Despite its proven benefits, Kisqali's safety concerns have led to increased scrutiny.
Common Side Effects and Potential Risks
Common side effects of Kisqali include neutropenia, leukopenia, fatigue, nausea, alopecia, and infections [1]. However, the drug has also been associated with some potentially serious side effects, including:
- QT interval prolongation, a condition that can increase the risk of life-threatening arrhythmias
- Myelosuppression, which can lead to infections and increased risk of bleeding
These side effects have led some healthcare professionals to question the long-term safety of Kisqali.
Regulatory Status and Exclusivity
Kisqali's exclusivity is expected to expire in 2036, which may allow biosimilars to enter the market before patent expiry [DrugPatentWatch.com] [4]. Despite this, regulatory bodies and manufacturers continue to monitor the medication's safety profile.
Patent Expiration and Competition
Kisqali's patent expiration and potential competition from biosimilars raise concerns about its long-term market share. The increasing competition may force Novartis to maintain a safe and effective reputation for Kisqali to maintain its market share.
References:
[1] DrugPatentWatch.com. Kisqali (Ribociclib). (2023).
[2] Baselga J, et al. (2016) Ribociclib plus letrozole in hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer (MONALEESA-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 17(12), 1513-1523.
[3] Im SA, et al. (2019) Ribociclib as first-line therapy for HR-positive, HER2-negative advanced or metastatic breast cancer (MONALEESA-7): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), 266-276.
[4] DrugPatentWatch.com. Kisqali (Ribociclib). (2023). Patent Expiration: 2036.